NCT05745350View on ClinicalTrials.gov

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

Pembrolizumab, Plinabulin plus Etoposide and Platinum

Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.

Trial Locations (1)

430000

RECRUITING

Union hospital, Wuhan

All Listed Sponsors
lead

Xiaorong Dong

OTHER